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ABSTRACT
Introduction: Recent evidence shows that oxidative stress seems to be related with 
the pathophysiology of X-linked adrenoleukodystrophy (X-ALD), a neurodegenerative 
disorder.
Methods: In the present study, the in vitro effect of N-acetyl-L-cysteine (NAC) on 
glutathione (GSH) and sulfhydryl levels in X-ALD patients was evaluated.
Results: A significant reduction of GSH and sulfhydryl content was observed in X-ALD 
patients compared to the control group. Furthermore, 5 mM of NAC, in vitro, led to an 
increase in GSH content and sulfhydryl groups in these patients.
Conclusion: These data probably indicate that an adjuvant therapy with the antioxidant 
NAC could improve the oxidative imbalance in X-ALD patients.
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X-linked adrenoleukodystrophy (X-ALD) is a peroxisomal disorder that affects 
at least 1 in 17,000 males1. Phenotypic variability is remarkable, ranging from 
severe and rapidly progressive forms (i.e., childhood cerebral form, CCER) to 
slowly progressive paraparesis compatible with life1.
Hexacosanoic acid (C26:0) and tetracosanoic acid (C24:0) are saturated 
fatty acids that accumulate in tissues and body fluids1. The exact mechanisms 
underlying brain damage in X-ALD are poorly elucidated. Some researchers 
have proposed that oxidative stress represents a hallmark in the pathogenesis 
of X-ALD2-4.
Glutathione  (GSH) deficiency  is  associated with  several  pathological 
conditions, since the glutathione system provides the main cellular protection 
against oxidative damage. Cellular redox balance is assured by equilibrated 
ratios among glutathione forms; therefore, a decrease in GSH or an increase in 
its oxidized form (GSSG) reflects an oxidative perturbation in cell metabolism5.
The antioxidant capacity of NAC has been proposed based on data from 
in vitro studies, in which this compound has been shown to reduce oxidant-induced 
cell damage, acting as a cysteine prodrug and a GSH precursor6. NAC can also 
reduce disulphide bonds in proteins, scavenge free radicals and bind metals to 
form complexes7. There are several in vitro and in vivo studies involving NAC 
action on X-ALD treatment8-11. Considering that NAC has been proposed as a 
GSH precursor, the purpose of this study was to analyze the in vitro effect of 
NAC on GSH and sulfhydryl levels in X-ALD patients.
METHODS
Subjects
A total of eight X-ALD patients [four heterozygotes (HTZ), one Addison-only 
and three CCER] were included in this study. These patients had their diagnosis 
confirmed by determination and mutation analysis of very long chain fatty 
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acids. The control group consisted of eight healthy 
subjects. This study was approved by the Ethics 
Committee of Hospital de Clínicas de Porto Alegre, 
RS, Brazil (protocol number 13-0247), and all subjects 
or parents gave written informed consent.
Mutation Analysis
Using 10 polymerase chain reactions (PCRs), it 
was possible to screen the entire coding sequence 
of the ABCD1 gene and intron-exon boundaries. 
All samples were screened by single strand 
conformational polymorphism analysis followed by 
automated DNA sequencing to establish the specific 
mutation. Amplicons with mobility shift were purified 
with Exo-SAP (GE Healthcare) and submitted to 
automated sequencing on ABI 3100 Genetic Analyzer 
using BigDye, version 3.0 (Life Technologies). Mutations 
were confirmed by reverse strand PCR sequencing.
Sample Collection and in Vitro Assay
Venous blood was collected under sterile conditions 
in heparinized vials. Immediately, aliquots of whole 
blood cells were incubated with NAC (2.5 and 5 mM) 
for 6 hours at 37 °C8,12. Then, the blood was centrifuged 
at 1000 ×g for 10 minutes and plasma was removed 
by aspiration, aliquoted and frozen at −80 °C until 
sulfhydryl determination. Erythrocytes were washed 
three times with cold saline solution, lysated with water 
and frozen at −80 °C until GSH analysis. NAC was 
diluted with phosphate-buffered saline (PBS buffer) 
on the day of use. The proportion of blood and 
antioxidant solutions diluted in PBS buffer was 1:3.
Reduced GSH Content in Erythrocytes
To measure GSH levels, lysates of erythrocytes were 
processed as described by Browne and Armstrong13. 
Results were expressed as nmol/mg protein.
Total Plasmatic Level of Sulfhydryl Groups
The plasmatic concentration of sulfhydryl groups 
was determined as described by Aksenov and 
Markesbery14. The sulfhydryl content is inversely 
correlated to oxidative damage to proteins. Results 
were reported as μmol TNB/mg protein.
Protein Determination
Plasma and erythrocyte protein concentrations 
were determined, respectively, by Biuret method 
— using the commercial kit of Labtest (Labtest 
Diagnóstica, Lagoa Santa, MG, Brazil) — and by 
the method of Lowry et al.15.
Statistical Analysis
Data were expressed as mean ± standard error of 
the mean (SEM). Comparisons between means were 
analyzed by one-way analysis of variance (ANOVA) 
followed by Duncan’s post hoc test. Differences 
were  considered  statistically  significant when P 
value was lower than 0.05. Statistical analyses were 
performed using the Statistical Package for the Social 
Sciences (SPSS Inc., Chicago, IL, USA — SPSS, 
version 19.0) software, and graphics were produced 
using the GraphPad Prism (GraphPad Software 
Inc., San Diego, CA, USA — version 5.0) software.
RESULTS
Patient and Control Information
Table 1 shows patient and control information 
(average and standard deviation of age, gender 
and phenotype).
In vitro effect of NAC on GSH content
Figure 1 shows GSH erythrocytes levels and 
the in vitro effect of NAC (2.5 and 5 mM) on GSH 
content in X-ALD patients (HTZ, CCER and Addison-
only). These three phenotypes were included in 
the same group because there was no significant 
difference in GSH levels between them [mean 
and SEM of female HTZ: 0.87 ± 0.82; mean and 
SEM of male patients (including the Addison-only 
patient): 0.66 ± 0.90, P = 0.68, Duncan’s post hoc 
test]. GSH concentration significantly decreased in 
these patients and 5 mM of NAC increased these 
levels, reaching control values [F(3, 19) = 10.41, 
P < 0.001].
Table 1: Patients and controls’ information.
Subjects Ages (years-old) Phenotypes/genders
Patient 1 29 Heterozygote woman
Patient 2 38 Heterozygote woman
Patient 3 49 Heterozygote woman
Patient 4 50 Heterozygote woman
Patient 5 9 Cerebral form male
Patient 6 9 Cerebral form male
Patient 7 14 Cerebral form male
Patient 8 14 Addison-only male
Mean ± SD 27.12 ± 16.77 -
Control 1 23 Male
Control 2 23 Male
Control 3 23 Male
Control 4 24 Male
Control 5 26 Woman
Control 6 26 Woman
Control 7 27 Woman
Control 8 30 Woman
Mean ± SD 25.25 ± 2.49 -
http://seer.ufrgs.br/hcpa Clin Biomed Res 2017;37(1) 35
N-acetyl-L-cysteine effect on glutathione and sulfhydryl levels in X-ALD patients
In vitro effect of NAC on Sulfhydryl content
Figure 2 shows sulfhydryl plasma levels and the 
in vitro effect of NAC (2.5 and 5 mM) on sulfhydryl content 
in X-ALD patients (HTZ, CCER and Addison-only). 
These three phenotypes were included in the same 
group because there was no significant difference in 
sulfhydryl content between them [mean and SEM of 
female HTZ: 0.29 ± 0.11; mean and SEM of male patients 
(including the Addison-only patient): 0.38 ± 0.10, P = 
0.25, Duncan’s post hoc test]. Sulfhydryl content was 
significantly reduced in these patients and 5 mM of 
NAC increased these levels until they reached control 
values [F(3.20) = 16.47, P < 0.001].
DISCUSSION
Several studies have shown that oxidative stress 
is induced in X-ALD patients, including oxidative 
damage to protein, lipids, and reduction of antioxidant 
capacity4,5,16. Previous research has demonstrated 
a reduction in GSH and sulfhydryl content in X-ALD 
patients5,17. Interestingly, low levels of GSH have 
also been reported in an animal model for X-ALD9. 
The present study showed that X-ALD patients had 
lower GSH and sulphydryl levels compared to the 
control group, which is consistent with the literature. 
Besides, 5 mM of NAC, in vitro, increased GSH content 
and sulfhydryl groups in these patients.
GSH plays a wide variety of physiological roles and 
its antioxidant effects depend on the presence of the 
free sulfhydryl group as a ready source of reducing 
equivalents to quench radical species. GSH also acts 
as a “scavenger” of free radicals18. The limiting step of 
the GSH synthesis involves conjugation of cysteine with 
L-glutamate, while L-glycine is added in a subsequent 
synthetic step by GSH synthase. GSH depletion is a 
feature of a wide range of neuropsychiatric disorders, 
including Alzheimer and Parkinson diseases, and in 
some inborn errors of metabolism5,19.
Adjuvant therapies with antioxidant have been 
studied in disease-associated oxidative stress. NAC is 
a cysteine prodrug with an antioxidant activity attributed 
to its sulfhydryl group, which provides protection against 
oxidative and metabolic processes. NAC supplies 
the cysteine necessary for GSH synthesis and has 
proven to be effective in treating disease-associated 
oxidative stress7.
It has been shown that NAC crosses the blood-brain 
barrier, accumulated in the brain, and reverses memory 
impairment and brain oxidative stress in aged mice20. 
Additionally, in some murine models of Alzheimer 
disease, the administration of NAC buffered oxidative 
damage21. In an animal model of Duchenne muscular 
dystrophy,  the  treatment with NAC  significantly 
decreased the oxidation of GSH and protein thiols, 
and enhanced muscle protein thiol content22.
In a clinical trial with Gaucher and Parkinson patients, 
NAC increased whole blood GSH/GSSG ratio and GSH 
concentration in the brain23. Rushworth et al.24 suggested 
that NAC might be useful not only for promoting GSH 
depletion, but also because NAC-derived cysteine 
can potentially lead to an increase in the release of 
glutamate from astrocytes resulting in activation of 
neuronal glutamate receptors.
Figure 1: The in vitro effect of N-acetyl-L-cysteine (NAC) 
(2.5 and 5 mM) on GSH levels in erythrocytes from X-ALD 
patients. Data represent mean ± standard error of the mean. 
***P < 0.001 compared to the control group and ###P < 0.001 
compared to X-ALD patients with NAC 2.5 mM and X-ALD 
patients [one-way analysis of variance (ANOVA) followed 
by Duncan’s multiple range test].
Figure 2: The in vitro effect of N-acetyl-L-cysteine (NAC) 
(2.5 and 5 mM) on sulfhydryl content in plasma from 
X-ALD patients. Data represent mean ± standard error 
of the mean. ***P < 0.001 compared to the control group 
and ###P < 0.001 compared to X-ALD patients with NAC 
2.5 mM and X-ALD patients [one-way analysis of variance 
(ANOVA) followed by Duncan’s multiple range test].
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Regarding studies involving the effect of NAC 
on X-ALD, Tolar et al.11 reported that peri-transplant 
administration of NAC was protective from fulminant 
demyelination in advanced symptomatic X-ALD patients. 
It was also seen that a pre-treatment with arginine 
and NAC inhibited nitrite and superoxide production 
in glial cells enriched with C26:08. Additionally, NAC 
in combination with other antioxidants reversed 
oxidative damage and energetic failure in an animal 
model for X-ALD10.
As to the underlying mechanisms by which NAC 
increases sulfhydryl and GSH levels, it is possible to 
assume that this action is probably due to stimulation 
of enzymes related to the GSH synthesis or to 
non-enzymatic mechanisms related to scavenger 
properties of free radicals.
Finally, the present results confirm former reports 
showing the role of oxidative stress on X-ALD and 
demonstrate, for the first time in the literature, the 
in vitro protective effect of NAC on GSH and sulfhydryl 
content in this disease. Therefore, this study underscores 
the pertinence of using antioxidants as an adjuvant 
therapy for X-ALD to improve oxidative imbalance in 
X-ALD patients. However, the present in vitro study 
should be interpreted with caution and more in vivo 
experiments are necessary to elucidate this issue.
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